Catalyst

Slingshot members are tracking this event:

Sangamo Therapeutics (SGMO) to submit IND in 2018 for cDNA gene therapy, which is designed to treat Fabry disease

Source Link:
https://seekingalpha.com/article/4072014-sangamo-therapeutics-sgmo-ceo-sandy-macrae-q1-2017-results-earnings-call-transcript?page=2

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
SGMO Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Feb 20, 2019
Occurred Source:
https://investor.sangamo.com/news-releases/news-release-details/sangamo-announces-fda-acceptance-ind-application-st-920-gene
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Cdna, Fabry Disease, Ind Filing
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.